Exo-101
Tissue Regeneration, Inflammatory Diseases
Pre-clinicalActive
Key Facts
Indication
Tissue Regeneration, Inflammatory Diseases
Phase
Pre-clinical
Status
Active
Company
About Exogenus Therapeutics
Exogenus Therapeutics is a private, pre-clinical stage biotech pioneering exosome-based therapeutics. Its core technology involves isolating and preconditioning small extracellular vesicles from umbilical cord blood mononuclear cells to produce a product with anti-inflammatory, immunomodulatory, and regenerative properties. The company has secured key international patents, partnered with Lonza for GMP process development, and is advancing its lead candidate, Exo-101, toward clinical trials targeted for 2027. Exogenus operates a collaborative R&D model to expand its pipeline and applications.
View full company profile